Adaptive Biotechnologies posts Q2 2026 revenue growth, plans Immune Medicine separation
The company raised full-year MRD revenue guidance and disclosed a $345 million convertible notes deal alongside a leadership change for co-founder Harlan Robins.
Adaptive Biotechnologies Corporation reported financial results for the quarter ended June 30, 2026 in an 8-K filed July 29, 2026. Revenue for the second quarter of 2026 reached $71.6 million.1 The MRD segment made up 92% of that revenue and expanded 33% compared with the second quarter of 2025.1
Test volume for the company's MRD diagnostic also rose. The clonoSEQ test delivered 36,111 tests in the quarter, a 43% increase from the same period a year earlier.1
On the financing side, Adaptive closed a $345 million zero-coupon convertible senior notes offering, used the proceeds to pay off its OrbiMed Purchase Agreement, and said the move gives it more flexibility for strategic priorities.1 Separately, the company said it plans to separate its MRD and Immune Medicine businesses.1
Leadership is shifting alongside the planned separation. On July 24, 2026, Chief Scientific Officer and co-founder Dr. Harlan Robins moved into a strategic consultant role, where the company expects him to support MRD research and development and the Immune Medicine separation process.1 The filing states there were no disagreements or performance issues tied to his decision.1
On guidance, Adaptive raised its full-year 2026 MRD revenue outlook to a range of $268 million to $278 million, implying growth of 26% to 31% for the year.1 Net loss for the quarter was $39.9 million, compared with $25.6 million in the same period last year.1 Cash, cash equivalents and marketable securities stood at $371.7 million as of June 30, 2026, including $15.1 million held by Digital Biotechnologies, Inc.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.